ArticleFrontiers in immunology2020
NOD2/RIG-I Activating
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Probing Immune Signatures of Conjugated Pattern Recognition Receptor Ligands Identifies Chimeras with Potent Adjuvant and Antitumor Activities.Journal of medicinal chemistry · 2026Article
- Immunological mechanistic action of intravenous BCG-mediated protection against tuberculosis.Cellular and molecular life sciences : CMLS · 2026Review
- Type I interferons in tuberculosis pathogenesis and prevention.Trends in microbiology · 2026Review
- Broad innate immune activation enhances the protective efficacy of rBCG-LTAK63 againstFrontiers in immunology · 2026Article
- Cross-species blood transcriptional correlates of BCG-mediated protection against tuberculosis include innate and adaptive immune processes.JCI insight · 2025Article
- Adjunctive beneficial effect of c-di-GMP, a STING agonist, in enhancing protective efficacy of TLR4-adjuvanted tuberculosis subunit vaccine formulations.Journal of biomedical science · 2025Article
- Covalent Polymer-RNA Conjugates for Potent Activation of the RIG-I Pathway.Advanced healthcare materials · 2025Article
- Proofreading mechanisms of the innate immune receptor RIG-I: distinguishing self and viral RNA.Biochemical Society transactions · 2024Review
- Activation of host nucleic acid sensors byCritical reviews in microbiology · 2024Review
- TRAF6 triggers Mycobacterium-infected host autophagy through Rab7 ubiquitination.Cell death discovery · 2023Article
- Blood transcriptional correlates of BCG-induced protection against tuberculosis in rhesus macaques.Cell reports. Medicine · 2023Article
- A nod to the bond between NOD2 and mycobacteria.PLoS pathogens · 2023Review
- BCGΔBCG1419c increased memory CD8Scientific reports · 2022Article
- CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.Viruses · 2022Article
- NOD2 signaling in CD11c + cells is critical for humoral immune responses during oral vaccination and maintaining the gut microbiome.Scientific reports · 2022Article
- Advance in strategies to build efficient vaccines against tuberculosis.Frontiers in veterinary science · 2022Review
- Immunization with CSP and a RIG-I Agonist is Effective in Inducing a Functional and Protective Humoral Response AgainstFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Arshad KhanDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Vipul K SinghDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Abhishek MishraDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Emily SoudaniDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Pearl BakhruDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Christopher R SinghDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Dekai ZhangInstitute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, United States.
David H CanadayDivision of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH, United States.
Anjaneyulu SheriSpring Bank Pharmaceuticals, Inc., Hopkinton, MA, United States.
Seetharamaiyer PadmanabhanSpring Bank Pharmaceuticals, Inc., Hopkinton, MA, United States.
Sreerupa ChallaSpring Bank Pharmaceuticals, Inc., Hopkinton, MA, United States.
Radhakrishnan P IyerSpring Bank Pharmaceuticals, Inc., Hopkinton, MA, United States.
Chinnaswamy JagannathDepartment of Pathology and Genomic Medicine, Center for Human Infectious Diseases, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.
Weill Cornell Medicine · USSpring Bank Pharmaceuticals (United States) · USCase Western Reserve University · USCornell University · USHouston Methodist · USTexas A&M Health Science Center · US
Funding
Molecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6MNIAID NIH HHS T32 AI055449
Abstract
Tuberculosis (TB) caused by
Indexed as
Adjuvants, ImmunologicAnimalsAntigen PresentationAntigens, BacterialBCG VaccineChromobox Protein Homolog 5CytokinesDendritic CellsImmunologic MemoryImmunomodulationMacrophagesMiceMycobacterium tuberculosisNod2 Signaling Adaptor ProteinProtein BindingReceptors, Cell SurfaceAdjuvants, ImmunologicAntigens, BacterialBCG VaccineCBX5 protein, humanChromobox Protein Homolog 5CytokinesNod2 protein, mouseNod2 Signaling Adaptor ProteinReceptors, Cell SurfaceRobo3 protein, mouseRoundabout Proteinsadjuvantsantigen presentationBCG vaccineinarigivirinflammasomeNOD2RIG-Ituberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.